Bacillus Calmette-Guerin (BCG)
Indications
Superficial Bladder Cancer (see Bladder Cancer , [[Bladder Cancer]]): intravesical BCG
Pharmacology
Bacillus Calmette-Guerin (BCG) : an attenuated strain of bovine tuberculous bacterium and consists of living bacilli, dead microorganisms, and subcellular debris
Administration
Adverse Effects
Pulmonary Adverse Effects
Disseminated BCG Infection
Granulomatous Pneumonitis (see Interstitial Lung Disease-Etiology , [[Interstitial Lung Disease-Etiology]])
Epidemiology : occurs in <1% of cases
Clinical : fever, chills, night sweats, malaise, dyspnea, cough
Diagnosis
Chest CT: miliary or 2-8 mm nodular pattern (may have mediastinal + hilar lymphadenopathy)
FOB-TBB: caseating or non-caseating granulomas
Hypersensitivity Pneumonitis (see Hypersensitivity Pneumonitis , [[Hypersensitivity Pneumonitis]])
Diagnosis
CXR/Chest CT: interstitial infiltrates
FOB-BAL: alveolar lymphocytosis with increased T4/T8 ratio
Treatment : favorable response to steroids
Acute Lung Injury (see Acute Lung Injury-ARDS , [[Acute Lung Injury-ARDS]])
Other Adverse Effects
References
Granulomatous Pneumonitis Following Intravesical BCG, What Therapy Is Needed? Chest 1994;106:1624-26
Granulomatous Chest Disease Following Intravesical Bacillus Calmette-Guerin Immunotherapy. J Thorac Imaging • Volume 19, Number 1, January 2004
Hypersensitivity Pneumonitis Following Intravesical Bacille Calmette-Guérin Immunotherapy for Superficial Bladder Cancer. J Investig Allergol Clin Immunol 2009; Vol. 19(3): 230-232
Property of Kenneth J. Serio, MD. Author is not responsible for errors in content, site is for information purposes only.